The Grizzly, February 24, 1999

Moyer Named Most Outstanding Wrestler as UC Wins Centennial Conference Gold • Middle States Evaluation • Let\u27s Play the Greek Feud • Film Society Offers a Thursday Night Alternative • Opinion: Clinton\u27s Kosovo Policy a Step in the Right Direction; Real Menace of Substance Abuse; Is Apathy a Threat to the Quality of Life? Or Don\u27t You Care? • Biology Student Art in Berman • Cloud 9 • UC Swimming Improves at Championships • UC Basketball Drops Out of Playoffs With Heartbreak Loss • Women\u27s Basketball Finishes Season • Rough Week for UC Gymnastics • Wrestlers Win Conference Titlehttps://digitalcommons.ursinus.edu/grizzlynews/1435/thumbnail.jp

Parental beliefs, infant temperament, and marital quality: Associations with infant–mother and infant–father attachment.

The present research examined parental beliefs about the importance of the paternal caregiving role, mothers’ and fathers’ reports of infant temperament, and observed marital quality as predictors of infant-mother and infant-father attachment security, over and above the effects of parental sensitivity. Infants’ attachment security to mothers and fathers were observed in the Strange Situation at 12- and 13-months, respectively (N = 62 two-parent families). Hierarchical regression models revealed that mothers who viewed the paternal caregiving role as important were less likely to have securely attached infants, but only when infant fussiness was high. Additionally, fathers who viewed the paternal caregiving role as important were more likely to have securely attached infants, but only when infants’ fussiness or marital quality was high

The Grizzly, February 1, 2000

A Burning Question: Recent Rash of Fatal College Fires Sparks UC Students to Ask, Are We Safe? • Ursinus Struck Twice More with Ice, Rain and Snow • St. Louis Super in Clash with Titans • Grizzly Library Goes Virtual • Dickinson College Librarian Finally Free from Exile in Chinese Prison • Study Abroad Experience Proves to be a Valuable One • Opinion: After Iowa, Throw out the Rulebook, it\u27s Anybody\u27s Game; Where\u27s the Juice in Juice? • Meistersingers Tour Europe • Career Services Introduces Experience • Swimming Gears Up for Champs • Pair of Losses for UC • Bears Struggle in Conference Play • The Flud Warning • Ursinus Gymnastics Tramples Brockport • Sports Profile: Luther Owenshttps://digitalcommons.ursinus.edu/grizzlynews/1457/thumbnail.jp

The Grizzly, February 29, 2000

Phi Psi Sanctioned • UC Students Weather Winter Sickness • Meghan Gualtieri: Profile of a True UC Role Model • Ursinus\u27 Own Superbagger • GOP Race Tightens in Michigan and Arizona • Investors to Transform Mir Into Out-of-this-World Hotel • Opinion: Food and Diversity at Ursinus College; Fox\u27s Marry a Millionaire Fiasco Sends Wrong Message • A Student\u27s proTheatre: Halves • John Gwinn: Post-Modernist Extraordinaire? • Gymnastics Sustains Record-Breaking Run at Rutgers • UC Grad Bill Stiles Becomes Sports Information Director • Winter Track Season Ends Strong • Bears Captures Last Three Wins • Sports Profile: Yori Adegunwahttps://digitalcommons.ursinus.edu/grizzlynews/1461/thumbnail.jp

The Grizzly, February 15, 2000

UC Students Debate Pros, Cons of Pledging On Campus • Feelings of Brotherhood, Sisterhood Prevalent During Pledging Process • Employment Available for Graduating Seniors • True Love: Sorrow and Devotion • Hackers, Hijackers, and the Wide World of Sports • The Greeks Agree: Pledges Have no Free Will • Pledging: What\u27s the Big Deal Anyway? • muMs Schemes at Ursinus • Pat McGee to Jam at Ursinus • Music Review: The Alligator Blues Band • Gymnastics Tops RIC with Season High Score • Intramural 3 on 3 Action: Brains vs. Brute • Indoor Track Steps Up to Eight Way Challenge • Ursinus Wrestling Battles for 4-1 • Sports Profile: Shana Goanehttps://digitalcommons.ursinus.edu/grizzlynews/1459/thumbnail.jp

The Grizzly, April 11, 2000

Vandalism: Running Rampant in Reimert and the Quad • UC Gets Medieval in Annual Sport Fest • PBK Lecture Informative and Hilarious • Phi Psi Educates UC Greeks on Pledging Do\u27s and Don\u27ts • Students Take Center Stage at Airband 2000 • Service Day Calls UC Community to Action • Basket Bingo Allows Others to Make-a-Wish • Putting a Finger on Sexuality • RHA Behind the Scenes • Election Preview: CAB, RHA, USGA and Class Elections • Letters to the Editor • Thoughts from a Sophomore Chat: If Tuition Increases, Scholarships Must • UC Artists Unveil Photography Exhibit • The Voice of UC College Choir • Team Effort Puts UC in the Lead • Bears Quest for NCAA Tournament Continues • Softball Ranked 18th in Nation • Tennis Team Continues to Struggle • Golf Ties for Second with F&M • Track and Field Improves at Osprey Open • Sports Profiles: Joe Sprague; Sue Sobolewskihttps://digitalcommons.ursinus.edu/grizzlynews/1465/thumbnail.jp

The Grizzly, September 15, 1998

Where\u27s Your Money Going? • Kenneth Starr\u27s XXX-Files • Pfahler Hall Renovations: The Sound of Progress • Opinion: Has America Sunk to the Level of Terrorists?; Academic Computing: Beneficial or Detrimental?; How Efficient Will the New Mail System Be? • Poets in Our Midst • RLO = One Big Happy Family • The Man from La Mancha has Gone Home • Addition Made to the History Department • Statues Breathe Life into Ursinus • Elyssa Rundle: The Spirit of the Paint • Big Big Band at UC • New Addition to Ursinus Training Staff • Men\u27s Soccer Plagued by Injuries • Football Back on Track • Women\u27s Soccer Shuts Out Washington • Field Hockey Drops Two Close Ones • Hinkle Named Player of the Week • UC Cross Country • UC Volleyball Improves to 7-1https://digitalcommons.ursinus.edu/grizzlynews/1423/thumbnail.jp

Open‐label, clinical trial extension:Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

SummaryBackgroundSeladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory and anti‐pruritic effects.AimsTo evaluate the long‐term safety and efficacy of seladelpar in patients with PBC.MethodsIn an open‐label, international, long‐term extension study, patients with PBC completing seladelpar lead‐in studies continued treatment. Seladelpar was taken orally once daily at doses of 5 or 10 mg with dose adjustment permitted for safety or tolerability. The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non‐alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years.ResultsThere were no serious treatment‐related adverse events observed among 106 patients treated with seladelpar for up to 2 years. There were four discontinuations for safety, one possibly related to seladelpar. Among 53 patients who completed 2 years of seladelpar, response rates increased from years 1 to 2 for the composite endpoint (alkaline phosphatase [ALP] &lt;1.67 × ULN, ≥15% decrease in ALP, and total bilirubin ≤ULN) and ALP normalisation from 66% to 79% and from 26% to 42%, respectively. In those with elevated bilirubin at baseline, 43% achieved normalisation at year 2.ConclusionsSeladelpar was safe, and markedly improved biochemical markers of cholestasis and liver injury in patients with PBC. These effects were maintained or improved throughout the second year. Clinicaltrials.gov: NCT03301506; Clinicaltrialsregister.eu: 2017‐003910‐16.</jats:sec

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

BACKGROUND: Seladelpar is a potent and selective peroxisome proliferator-activated receptor-δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti-cholestatic, anti-inflammatory and anti-pruritic effects. AIMS: To evaluate the long-term safety and efficacy of seladelpar in patients with PBC. METHODS: In an open-label, international, long-term extension study, patients with PBC completing seladelpar lead-in studies continued treatment. Seladelpar was taken orally once daily at doses of 5 or 10 mg with dose adjustment permitted for safety or tolerability. The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non-alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years. RESULTS: There were no serious treatment-related adverse events observed among 106 patients treated with seladelpar for up to 2 years. There were four discontinuations for safety, one possibly related to seladelpar. Among 53 patients who completed 2 years of seladelpar, response rates increased from years 1 to 2 for the composite endpoint (alkaline phosphatase [ALP] <1.67 × ULN, ≥15% decrease in ALP, and total bilirubin ≤ULN) and ALP normalisation from 66% to 79% and from 26% to 42%, respectively. In those with elevated bilirubin at baseline, 43% achieved normalisation at year 2. CONCLUSIONS: Seladelpar was safe, and markedly improved biochemical markers of cholestasis and liver injury in patients with PBC. These effects were maintained or improved throughout the second year